RASSF8

Across TCGA pan-cancer cohorts, RASSF8 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RASSF8 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RASSF8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RASSF8 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, UCEC, and SARC are the cancer types where RASSF8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	II,III,IV	0.217	0.742	<.001	28	view →
UCEC	DFS	Median	III,IV	1.000	0.535	.023	20	view →
SARC	OS	Median	All	0.144	0.745	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RASSF8–SKCM (OS)

Open the SKCM breakdown →